Vincera Pharma Announces Completion of Business Combination and Listing on Nasdaq
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020
LIFESCI ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of LSAC and Encourages Investors to Contact the Firm
NEW YORK, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of LifeSci...
LifeSci Acquisition Corp. Announces Merger Agreement with Vincera Pharma, Inc. to Create New Publicly Listed Oncology Company
Vincera is expected to have approximately $60 million at closing to fund clinical and preclinical development pipeline